125 results
S-3
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
are a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. We have developed a portfolio of late-stage clinical … in this prospectus supplement.
S-3
THE COMPANY
Overview
We are a biopharmaceutical company focused on the development of innovative therapeutics
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
BioPharma Group plc (the “Company” or “Mereo”) is United Kingdom (“U.K.”) based biopharmaceutical company focused on the development of innovative … -looking statements.
Overview
We are a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. We have
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
15 May 24
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
on the development of innovative therapeutics for rare diseases. The Company has two rare disease product candidates, setrusumab for the treatment
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
on the development of innovative therapeutics for rare diseases. We have developed a portfolio of late-stage clinical product candidates. Our two rare disease … infrastructure to commercialize the products in key markets.
Our Strategy
We intend to become a leading biopharmaceutical company developing innovative
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
shares of the Company.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics
8-K
EX-99.1
fbnobb
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
6-K
EX-99.1
3dd150ysz6
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
6-K
EX-99.1
d4lzqlj84uz2sm3wga
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.2
4mbzwdte68ebwp9
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
juq3s b1mm
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.3
63k7d2
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
dtjnz3 ai52
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.1
4kugstek65z2 1la3av
8 May 23
Current report (foreign)
4:07pm
6-K
EX-99.1
foqw57x0 3ff
5 May 23
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5:06pm
6-K
EX-99.1
za9q fx8dyqxmp2v71
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.2
u727qb
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.1
y9qjg
2 Nov 22
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
4:07pm
6-K
EX-99.1
8iahyr01ubnz
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.1
oy0huv0 2aam
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
n6usjt sr
18 Oct 22
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
7:07am